HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients
- 1 January 2002
- journal article
- Published by Elsevier in Kidney International
- Vol. 61 (1) , 297-304
- https://doi.org/10.1046/j.1523-1755.2002.00109.x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Effect of simvastatin on the lipid profile of hemodialysis patientsKidney International, 1999
- Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patientsKidney International, 1999
- Clinical epidemiology of cardiovascular disease in chronic renal diseaseAmerican Journal of Kidney Diseases, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysisAtherosclerosis, 1997
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Effect of simvastatin treatment on the dyslipoproteinemia in capd patientsAtherosclerosis, 1991
- Prevalence of serum lipid abnormalities in chronic hemodialysisMetabolism, 1977
- Accelerated Atherosclerosis in Prolonged Maintenance HemodialysisNew England Journal of Medicine, 1974